These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31706943)

  • 21. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
    van Erpecum KJ; Sonneveld MJ
    Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149
    [No Abstract]   [Full Text] [Related]  

  • 22. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
    Choi WM; Choi J; Wong GL; Han S; Lim YS
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):87. PubMed ID: 33444532
    [No Abstract]   [Full Text] [Related]  

  • 24. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Kamal F; Khan MA; Ahmed A; Nair S
    Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Authors' response: Additional more factors should be included in predicting risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Chang JW; Kim SU
    J Viral Hepat; 2021 Mar; 28(3):574. PubMed ID: 33305419
    [No Abstract]   [Full Text] [Related]  

  • 27. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Wen Z; Feng Y; Yan X
    J Hepatol; 2021 Jan; 74(1):245-246. PubMed ID: 33008623
    [No Abstract]   [Full Text] [Related]  

  • 28. Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    Papatheodoridis G; Sypsa V; Lampertico P
    J Hepatol; 2021 Jan; 74(1):246-247. PubMed ID: 32988659
    [No Abstract]   [Full Text] [Related]  

  • 29. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
    Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
    J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Kim BK; Kim SU
    Hepatology; 2021 Jan; 73(1):466. PubMed ID: 32602169
    [No Abstract]   [Full Text] [Related]  

  • 34. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
    Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
    J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Wang BQ; Wang YL; Shi KQ
    Liver Int; 2017 Feb; 37(2):309-310. PubMed ID: 27791331
    [No Abstract]   [Full Text] [Related]  

  • 36. Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Kao JH
    Liver Int; 2017 Feb; 37(2):310-311. PubMed ID: 28070982
    [No Abstract]   [Full Text] [Related]  

  • 37. Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Yuan G; Yao J; Yu J; Xie X; He S
    Hepatology; 2021 Mar; 73(3):1240. PubMed ID: 33016343
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
    Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.